Press Releases

Calgary, Alberta--(Newsfile Corp. - May 9, 2024) - Baytex Energy Corp. (TSX: BTE) (NYSE: BTE) reports that all matters presented for approval at the annual meeting of shareholders held today were approved. A total of 316,924,889 common shares being 38.56% of Baytex's issued and outstanding shares were represented at the meeting.

At the meeting, all of the nominees proposed as directors were duly elected. Results of the vote are set out below:

• Adalimumab-aaty will be priced at an 85% discount to HUMIRA® (adalimumab)
• Branded and unbranded versions of Celltrion USA's adalimumab biosimilar help provide more affordable options for patients

JERSEY CITY, N.J., May 9, 2024 /PRNewswire/ -- Celltrion USA announced today that adalimumab-aaty, the company's high-concentration (100 mg/mL) and citrate-free formulation biosimilar to HUMIRA ® (adalimumab), is now available at a low wholesale acquisition cost (WAC).... (continue reading...)

BRENTWOOD, Tenn.--(BUSINESS WIRE)-- Lifepoint Health, Inc. (the “Company”) today announced that it has priced its offering of $800 million aggregate principal amount of 10.000% Senior Notes due 2032 (the “Notes”) at an issue price of 100.000% in a private offering that is exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”). As previously announced, on May 8, 2024, the Company also launched a new... (continue reading...)

NEW YORK, May 9, 2024 /PRNewswire/ -- Reveald, an industry founder of Continuous Threat Exposure Management, has expanded its capabilities by acquiring rThreat and creating the Epiphany Validation Engine (EVE) to enhance AI-driven cyber resilience. EVE is a state-of-the-art emulation technology that enables security operators to assume the role of attackers to validate cybersecurity readiness and controls validating malware, TTPs, and controls, while allowing... (continue reading...)

- Poster will highlight interim evaluation update of photoimmunotherapy based on Alluminox™ platform using ASP-1929 in combination with anti-PD-1- Japanese treating physicians will present a poster on the latest data on photoimmunotherapy in clinical practice in Japan for recurrent nasopharyngeal carcinoma

Disclaimer: Rakuten Medical's therapies based on Alluminox™ platform are investigational outside of Japan.

SAN DIEGO, May 9, 2024 /PRNewswire/ -- Rakuten... (continue reading...)